- Home
- GERN vs ATUS Comparison
GERN vs ATUS Comparison
Compare GERN & ATUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- ATUS
- Stock Information
- Founded
- GERN 1990
- ATUS 2015
- Country
- GERN United States
- ATUS United States
- Employees
- GERN N/A
- ATUS N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- ATUS Cable & Other Pay Television Services
- Sector
- GERN Health Care
- ATUS Telecommunications
- Exchange
- GERN Nasdaq
- ATUS Nasdaq
- Market Cap
- GERN 974.5M
- ATUS 1.0B
- IPO Year
- GERN 1996
- ATUS 2017
- Fundamental
- Price
- GERN $1.32
- ATUS $2.56
- Analyst Decision
- GERN Buy
- ATUS Buy
- Analyst Count
- GERN 8
- ATUS 6
- Target Price
- GERN $3.71
- ATUS $2.88
- AVG Volume (30 Days)
- GERN 9.4M
- ATUS 6.1M
- Earning Date
- GERN 08-07-2025
- ATUS 08-07-2025
- Dividend Yield
- GERN N/A
- ATUS N/A
- EPS Growth
- GERN N/A
- ATUS N/A
- EPS
- GERN N/A
- ATUS N/A
- Revenue
- GERN $116,293,000.00
- ATUS $8,855,764,000.00
- Revenue This Year
- GERN $160.12
- ATUS N/A
- Revenue Next Year
- GERN $55.01
- ATUS N/A
- P/E Ratio
- GERN N/A
- ATUS N/A
- Revenue Growth
- GERN 22264.04
- ATUS N/A
- 52 Week Low
- GERN $1.17
- ATUS $1.52
- 52 Week High
- GERN $5.06
- ATUS $3.20
- Technical
- Relative Strength Index (RSI)
- GERN 40.66
- ATUS 64.06
- Support Level
- GERN $1.36
- ATUS $2.53
- Resistance Level
- GERN $1.48
- ATUS $2.79
- Average True Range (ATR)
- GERN 0.09
- ATUS 0.13
- MACD
- GERN -0.02
- ATUS 0.07
- Stochastic Oscillator
- GERN 7.41
- ATUS 74.61
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About ATUS Altice USA Inc.
Altice Europe acquired privately held US cable company Suddenlink in 2015 and Cablevision in 2016. Suddenlink's networks provide television, internet access, and phone services to roughly 4.5 million US homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. Cablevision provides comparable services to about 5.5 million homes and business in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Altice USA, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018. Altice USA also owns News 12 Networks, which broadcasts local news in New York.